The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The global age-related macular degeneration (AMD) market is poised for growth, projecting an increase from $8.49 billion in 2022 to $9.17 billion in 2023, marking a commendable compound annual growth rate (CAGR) of 8%. However, recent geopolitical events, specifically the Russia-Ukraine war, have cast a shadow over the global economic recovery from the COVID-19 pandemic. The repercussions include economic sanctions, commodity price surges, and supply chain disruptions, leading to inflation across goods and services. Despite these challenges, the age-related macular degeneration market is anticipated to reach $12.18 billion by 2027, reflecting a CAGR of 7.3%.

Propelling Factors: Rising AMD Prevalence

The upward trajectory of the age-related macular degeneration (AMD) market is significantly influenced by the increasing prevalence of AMD, a progressive eye condition impacting the macula—a critical part of the retina responsible for central vision. Treatments for AMD play a pivotal role in mitigating the severity of the disease, providing support to those affected by retinal disorders. Reports from Optimaxa reveal a global prevalence of 196 million individuals suffering from AMD in February 2023, projected to reach 288 million by 2040, constituting 8.7% of the world’s population. This surge in AMD prevalence propels the demand for effective treatments, driving the growth of the AMD market.

Leading Players Shaping the Landscape

Major players in the age-related macular degeneration market include F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., and Bausch Health Companies Inc. These key players, alongside others like Regeneron Pharmaceuticals Inc., Amgen Inc., and AbbVie Inc., contribute to the dynamic and competitive nature of the AMD market.

Innovative Solutions: A Key Trend

Product Innovation: Fueling Market Dynamics

A significant trend gaining momentum in the age-related macular degeneration market is the emphasis on product innovation. Major companies in the market are channeling their efforts into developing innovative products and drugs, solidifying their positions. Notably, in October 2021, Genentech Inc. received regulatory approval for Susvimo (ranibizumab), a novel therapy for wet AMD patients. This sustained-release implant delivers ranibizumab, preventing abnormal blood vessel growth in the retina. Susvimo provides a more convenient and less invasive treatment option than traditional eye injections, showcasing the industry’s commitment to advancing patient-centric solutions.

Segmentation Dynamics: Understanding Market Variability

1) By Type

The age-related macular degeneration market unfolds across various types:

• Wet Age-Related Macular Degeneration (AMD)
• Dry Age-Related Macular Degeneration (AMD)

2) By Drug

Diverse drugs cater to varying needs:

• Eylea
• Lucentis
• Avastin
• Other Products

3) By Route of Administration

Treatment administration varies:

• Intravenous
• Intravitreal

4) By Distribution Channel

The market serves diverse channels:

• Hospital Pharmacy
• Specialty Pharmacy
• Online Pharmacy

Regional Dynamics: North America Leading, Asia-Pacific Rising
North America emerges as the largest region in the global age-related macular degeneration market in 2022. However, the spotlight is expected to shift towards Asia-Pacific, anticipated to be the fastest-growing region in the forecast period. The regional dynamic underscores the global impact and evolving nature of the AMD market.

View More On The Age-Related Macular Degeneration Market Report 2023 – https://www.thebusinessresearchcompany.com/report/age-related-macular-degeneration-global-market-report

Request A Sample Of The Global Age-Related Macular Degeneration Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=10845&type=smp

The Age-Related Macular Degeneration Global Market Report 2023  provides a comprehensive overview on the age-related macular degeneration market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the age-related macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Dry Eye Medication Global Market Report 2023
Macular Degeneration Treatment Global Market Report 2023
Generic Musculoskeletal Disorders Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model